Dendreon

Here's a quick look at nine of the best-performing biotech stocks of the past year. Achillion Pharmaceuticals (NASDAQ: ACHN) is up almost 88% year to date and about 37% higher just in the past month. This Connecticut-based biopharmaceutical company has three drugs in clinical trials to treat...

Citadel Securities has published a report on Dendreon (NASDAQ: DNDN) initiating coverage of the biotech company. In the report, Citadel Securities wrote, "We expect competitor data from Johnson & Johnson's oral prostate cancer drug ZYTIGA to be available during 2012, with an interim look...

According J.P. Morgan, Dendreon (NASDAQ: DNDN) Overweight rating is reiterated. J.P. Morgan said that it reiterates its OW rating on DNDN ahead of important near-term developments. “For the second time this year, the company is approaching a clustering of events that could have significant...

Goldman Sachs has initiated coverage on Dendreon Corporation (NASDAQ: DNDN) with a Buy rating and $50 price target.

According to J.P. Morgan, Dendreon (NASDAQ: DNDN) Overweight rating is reiterated. J.P. Morgan said that it reiterates its OW rating on DNDN and are providing follow-up thoughts post the company's 1Q conference call. “See our earlier Quick Take for our initial thoughts on quarterly performance....

Citi is out with its report today on Dendreon (NASDAQ: DNDN), maintaining Hold. In a note to clients, Citi writes, "With the overhang on the NCA recently lifted, the stock will trade on Provenge sales going forward. While near term sales prospects look solid as the company just added capacity and...

J.P. Morgan is out with its report today on Dendreon (NASDAQ: DNDN), reiterating Overweight. In a note to clients, J.P. Morgan writes, "Reimbursement concerns can finally be put to rest after CMS released a draft guidance memo this afternoon that supports continued coverage of Provenge for the on-...

J.P. Morgan is reiterating its OW rating on Dendreon Corp. (NASDAQ: DNDN) “ahead of the anticipated CMS memo regarding the ongoing National Coverage Analysis of Provenge, which is expected later this week (by Wed March 30).” “We believe the Street broadly shares our view and expects confirmation...

Dendreon Corp. (DNDN) CEO Mitch Gold was on CNBC this morning to discuss the success and prospects of Provenge, a cellular immunotherapy that stimulates a patient's immune system to target and attack prostate cancer. “We've been fighting the war on cancer for 40 years,” Gold said. However, Dendreon...

In a report published by Deutsche Bank, Deutsche Bank wrote that Dendreon (NASDAQ: DNDN) may face future competition from Bavarian Nordic, a company developing a sligthly different cancer vaccine to prostate cancer called ProstVac. Deutsche Bank noted that this morning Bavarian Nordic reported...

J.P. Morgan is out with its report today on Dendreon (NASDAQ: DNDN), reiterating Overweight after visiting DNDN's newly constructed Provenge facility. In a note to clients, J.P. Morgan writes, "This was a productive trip that reinforced our high level of conviction in DNDN. Whether investors wait...

Speculative biotech company, Dendreon Corp. (NASDAQ: DNDN) shares are surging nearly 7% in mid day trading on rumors of a potential FDA approval of its prostate cancer drug Provenge by May 1. By mid day 4 million shares have already traded, average volume 2.2mil. The volume is being confirmed by...